A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis

In a phase 2 study of INCB050465 plus ruxolitinib in patients with myelofibrosis who previously had a suboptimal or loss of response to ruxolitinib alone, the combination demonstrated preliminary efficacy, and the daily 8-week/then once per week dosing regimen had a better toxicity profile than other PI3K inhibitors have shown.

 Blood (ASH Abstract)

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.